Solution for intravenous and intramuscular use 50 mg / ml.
2 ml – glass ampoules (5) – blister strip packaging (2) – packs of cardboard.
Mexiprim refers to heteroaromatic antioxidants. It has a wide range of pharmacological activity: it increases the body’s resistance to stress, has an anxiolytic effect, which is not accompanied by drowsiness and muscle relaxant effect, has nootropic properties, prevents and reduces learning and memory impairments, arising from aging and exposure to various pathogenic factors, has an anticonvulsant effect, exhibits antioxidant and antihypoxic properties, increases concentration and performance weakens the toxic effect of alcohol.
The drug improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of the blood, reduces platelet aggregation. Stabilizes the membrane structure of blood cells (red blood cells and platelets). It has a lipid-lowering effect, reduces the content of total cholesterol and low density lipoproteins.
The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the ratio of lipid protein, reduces the viscosity of the membrane, increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structurally functional organization of biomembranes, and transport neuron. Mexiprim increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
The maximum concentration of Mexiprim in plasma is in the range from 50 to 100 ng / ml.
The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively. Mexiprim in the human body is extensively metabolized with the formation of its glucuronoconjugated product. On average, within 12 hours, 0.3% of the unchanged drug and 50% in the form of a glucuronoconjugate from the administered dose are excreted in the urine. Mexiprim and its glucuronoconjugate are excreted most intensively during the first 4 hours after taking the drug. Urinary excretion rates of Mexiprim and its conjugated metabolite have significant individual variability.
Acute cerebrovascular accident (as part of complex therapy)
Anxiety conditions, neurotic and neurosis-like pulmonary syndromes of the brain, neurosis senile and atrophic processes, neuroinfection and intoxication)
Memory disorders and intellectual deficiency in the elderly
Exposure to extreme (stress) factors
Alcohol withdrawal syndrome with a predominance of neurosis-like and vegetative-vascular disorders
Acute intoxication with antipsychotics.
Acute hepatic and / or renal failure, increased individual sensitivity to the drug. Children’s age, pregnancy, breastfeeding – due to insufficient knowledge of the effect of the drug in these categories of patients.
Use during pregnancy and lactation
Currently, the possibility and safety of the use of Mexiprim during pregnancy and lactation has not been sufficiently studied, therefore the use of the drug in this category of patients is contraindicated.
Composition per 1 ml: Ethyl methylhydroxypyridine succinate – 50 mg
Water for injection – up to 1 ml.
Dosage and administration
mexiprim is administered intramuscularly or intravenously (in a stream or drop). Doses are selected individually. With the infusion method of administration, the drug should be diluted in physiological solution of sodium chloride. Treatment begins with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. Jet Mexiprim is administered slowly for 5-7 minutes, drip at a speed of 40-60 drops per minute. The maximum daily dose does not exceed 800 mg.
In acute cerebrovascular accidents, Mexiprim is used in combination therapy in the first 2-4 days, intravenously, in a dose of 200-300 mg once a day, then 100 mg intramuscularly 3 times a day. The duration of treatment is 10-14 days.
In case of discirculatory encephalopathy in the decompensation phase, Mexiprim should be administered intravenously, drip or drop at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg 2-3 times a day for the next 2 weeks. For the course of prevention of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days.
For mild cognitive impairment in elderly patients and anxiety disorders, the drug is administered intramuscularly in a daily dose of 100-300 mg per day for 14-30 days.
With withdrawal alcohol syndrome, Mexiprim is administered at a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days.
In acute intoxication with antipsychotics, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.
Rarely – nausea, dry oral mucosa, drowsiness, allergic reactions.
Compatible with psychotropic drugs. Increases the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa), reduces the toxic effect of ethyl alcohol.
Symptoms: sleep disturbance (insomnia, in some cases drowsiness).
Treatment: usually not required – symptoms disappear on their own within a day.
In severe cases, insomnia is recommended to take sleeping pills.
In the dark place at a temperature of no higher than 20 ° C. Keep out of the reach of children.
Pharmacy terms of delivery